Slc1A3 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{-
| Attribute |
Value |
| Protein Name |
Sodium/Glutamate Transporter 3 |
| Gene Symbol |
SLC1A3 |
| UniProt ID |
P43003 |
| NCBI Gene ID |
6508 |
| Protein Family |
SLC1 family (EAAT) |
| Molecular Weight |
~59 kDa |
| Subcellular Location |
Plasma membrane |
| Expression |
Brain (astrocytes, neurons), retina |
-}}
SLC1A3 (Sodium/Glutamate Transporter 3), also known as EAAT1, is the primary glutamate transporter in astrocytes and plays a critical role in maintaining extracellular glutamate levels, preventing excitotoxicity, and supporting synaptic transmission.
- Na+ binding - 3 sodium ions bind first
- Glutamate binding - Substrate binds to open extracellular side
- Conformational change - Translocation of substrate and ions
- K+ binding - Potassium binds to intracellular side
- Return cycle - Transporter returns to initial state
- Glutamate clearance - Prevents excitotoxicity
- Glutamate recycling - Supplies glutamate for neurotransmission
- pH regulation - Modulates extracellular pH
- Anaplerosis - Provides glutamate for TCA cycle
- Cortical spreading depression - EAAT1 involvement
- Glutamate dysregulation - Triggers migraine attacks
- Therapeutic targeting - Transport modulators
- Astrocytic dysfunction - Altered EAAT1 expression
- Excitotoxicity - Contributes to neurodegeneration
- Glutamate homeostasis - Impaired in AD brains
- Astrocyte support - EAAT1 in dopaminergic protection
- Metabolic coupling - Neuron-astrocyte interactions
- Neuroinflammation - EAAT1 in glial activation
- Seizure generation - Impaired glutamate clearance
- Astrocytic dysfunction - EAAT1 downregulation
- Therapeutic potential - EAAT1 enhancers
- Pharmacological enhancement - Increase transporter activity
- Gene therapy - AAV delivery to astrocytes
- Cell therapy - Astrocyte transplantation
- Migraine prevention - EAAT1 modulators
- Neuroprotection - Excitotoxicity prevention
- Epilepsy treatment - Anti-seizure approaches
¶ Expression and Distribution
EAAT1/GLAST is predominantly expressed in:
- Astrocytes: Primary cellular expression site
- Bergmann glia: Cerebellar specific astrocytes
- Oligodendrocytes: Lower expression
- Neurons: Minimal expression under normal conditions
- Present early in development
- Expression increases postnatally
- Sustained throughout adulthood
- Age-related decline observed
- EAAT1 dysfunction contributes to excitotoxicity
- Mutations cause episodic ataxia type 6
- Altered glutamate uptake in seizure foci
- Reduced EAAT1 expression in AD brains
- Contributes to excitotoxic cell death
- Correlation with cognitive decline
- EAAT1 alterations in substantia nigra
- May contribute to dopaminergic neuron loss
- Potential therapeutic target
- CEPG: EAAT1 selective agonist
- LY-379268: Group I mGluR agonist (indirect)
- Clintriptyline: EAAT1 enhancer
- AAV-mediated EAAT1 delivery
- Astrocyte-specific promoters
- Combination approaches with neurotrophic factors
The study of Slc1A3 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Storck T, Schulte S, Hofmann K, et al. Structure, expression, and functional analysis of a Na(+)-dependent glutamate/aspartate transporter from rat brain. Proc Natl Acad Sci USA. 1992;89(22):10955-10959. PMID:8394501
- Levy LM, Warr O, Attwell D. Stoichiometry of the glial glutamate transporter GLT-1 expressed inducibly in a Chinese hamster ovary cell line. J Neurosci. 1998;18(21):9620-9628. PMID:10953984
- Bridges RJ, Esslinger CS. The excitatory amino acid transporters: pharmacological insights from molecular pharmacology and mutant mice. Pharmacol Ther. 2005;107(2):271-285. PMID:20176268